Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454745 | 0.76 | NISCH (0.50) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL29598957 | 0.76 | NISCH (0.50) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL1673128 | 0.76 | — | — | |
| SCHEMBL78566 | 0.76 | NISCH (0.50) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL27985753 | 0.74 | DHFR (0.33) | PIM1METAP2KDM4ERECQLHTT | |
| SCHEMBL31372462 | 0.74 | NISCH (0.48) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL14053846 | 0.74 | NISCH (0.48) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL9794662 | 0.74 | NISCH (0.48) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL3640139 | 0.74 | NISCH (0.48) | PIM1NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL27985757 | 0.73 | PIM1 (0.34) | PIM1METAP2KDM4ERECQLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459235-B | Pyrazinyl pyrazoles | BAYER CROPSCIENCE AG | 2015-03-11 | — | — | CN | claimed |
| EP-2435420-B1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-04-03 | — | — | EP | claimed |
| US-20120190687-A1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG | 2012-07-26 | — | — | US | claimed |
| CN-102459235-A | Pyrazinyl pyrazoles | BAYER CROPSCIENCE AG | 2012-05-16 | — | — | CN | claimed |
| EP-2266973-A1 | Pyrazinylpyrazole | Bayer CropScience AG (DE) | 2010-12-29 | — | — | EP | claimed |
| WO-2010136145-A1 | PYRAZINYLPYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | WO | claimed |
| CN-111925370-B | Pyrazinopyrazoles naphthyridine compound and preparation method and application thereof | 湖北科苑生物药业有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| CN-106414473-B | Polyene macrolide derivatives | 盐野义制药株式会社 | 2020-03-13 | — | — | CN | disclosed |
| CN-107567503-A | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-104194380-B | The method of dyeing and lightening keratin materials in the presence of the reducing agent comprising fluorescent disulphide dye | 莱雅公司 | 2017-07-21 | — | — | CN | disclosed |
| US-9066945-B2 | Ectoparasiticidal active substance combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1383747-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-5102893-A | Anticholestrerol agents | WARNER-LAMBERT COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| US-4957971-A | Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis | WARNER-LAMBERT COMPANY (US) | 1990-09-18 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | PIM1 2673/4885NISCH 1679/4885CYP2D6 1568/4885 |
| US-20120190687-A1 | Pyrazinylpyrazoles | CYP4F3, CYP4B1, CYP1A2 | PIM1 1284/4885NISCH 73/4885CYP2D6 92/4885 |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | PIM1 4010/4885NISCH 645/4885CYP2D6 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.